Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AnaptysBio's Enterprise Value for the quarter that ended in Mar. 2026 was $813.9 Mil.
AnaptysBio's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnaptysBio EV-to-EBIT Related Terms
AnaptysBio EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AnaptysBio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HFQ vs FBRX, SNDX, BCAX: EV-to-EBIT Comparison
For the Biotechnology subindustry, AnaptysBio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnaptysBio EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnaptysBio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AnaptysBio's EV-to-EBIT falls into.
AnaptysBio's current Enterprise Value is $1,393.5 Mil.
AnaptysBio's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnaptysBio (LTS:0HFQ) has a EV-to-EBIT of 24.86 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AnaptysBio and its competitors. According to the industry distribution chart, AnaptysBio ranks #234 out of 365 companies in the Biotechnology industry, placing it in the top 64.1%.
Is AnaptysBio's EV-to-EBIT too high?
AnaptysBio's current EV-to-EBIT is 24.86. The Biotechnology industry median EV-to-EBIT is 15.95. AnaptysBio's value of 24.86 is 55.9% above this industry median. Based on the distribution chart, AnaptysBio ranks #234 out of 365 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AnaptysBio has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's EV-to-EBIT compare to FBRX and SNDX?
According to the Biotechnology industry distribution chart, AnaptysBio ranks #234 out of 365 companies for EV-to-EBIT. This places AnaptysBio in the lower half of its industry. The industry median EV-to-EBIT is 15.95. AnaptysBio's value of 24.86 is 55.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AnaptysBio's current EV-to-EBIT of 24.86 is 55.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AnaptysBio and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnaptysBio's current EV-to-EBIT is 24.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (LTS:0HFQ) is currently considered Fairly Valued. The stock's GF Value™ is $56.63, compared to a current price of $56.26 — trading 0.7% below its estimated fair value. The current EV-to-EBIT is 24.86 and 55.9% above the Biotechnology industry median of 15.95. AnaptysBio's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AnaptysBio (LTS:0HFQ), the current EV-to-EBIT is 24.86 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnaptysBio (LTS:0HFQ) Overvalued in 2026?
Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued.
The current stock price of $56.26 is trading 0.7% below its estimated GF Value™ of $56.63.
GuruFocus considers AnaptysBio to be Fairly Valued.
Key valuation signals for LTS:0HFQ:
EV-to-EBIT: 24.86
GF Value™: $56.63 vs. price of $56.26 (0.7% below fair value)
Industry Position: 55.9% above the Biotechnology median (#234 of 365)
No single metric tells the full story. See the LTS:0HFQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
59GF Score
Get the complete analysis for LTS:0HFQ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HFQ has been successfully added to your 
